How CBD interacts with prescription medications

The CYP450 mechanism in plain English

CYP enzymes are liver enzymes that break down most prescription drugs and many supplements. CYP3A4 alone metabolizes roughly 50% of all prescription medications; CYP2C9, CYP2C19, and CYP2D6 cover most of the rest. The body's drug-clearance system is built around these four enzymes.

When you give a CYP inhibitor at the same time as a drug that uses that enzyme, the drug accumulates in plasma beyond what the prescriber's dosing assumes. That's a drug interaction — not toxic in itself, but a deviation from expected dosing. Some deviations matter clinically; some don't.

CBD is a measurable inhibitor of CYP3A4, CYP2C9, and CYP2C19 at clinically achievable concentrations. Yamaori 2011 documented this inhibition in vitro; Doohan 2021 showed most cannabinoids (not just CBD) inhibit CYP2C9. Bansal 2023 took this from in vitro to clinical RCT and quantified the magnitude: 56–207% increase in CYP-substrate plasma exposure with CBD-dominant cannabis at ~750mg-equivalent/day.

The 750mg/day Bansal dose is closer to epilepsy research doses than to wellness doses. At 25–50mg/day — typical Reclaim customer usage — the magnitude is smaller but the mechanism is identical. Pharmacogenomic variation (CYP2D6 polymorphism per Anderson 2022) means the same dose has different effects in different people.

What the strongest evidence shows

Bansal 2023 — the clinical RCT

The most direct evidence we have. Eighteen healthy adults, randomized, CBD-dominant cannabis dosed to ~750mg CBD-equivalent. Concomitant CYP-substrate drugs showed plasma exposure increases of 56–207% across the substrate panel. The trial used research-grade doses, not wellness doses — important context — but it confirms in clinical-human terms what in vitro studies had predicted for over a decade.

Stöllberger 2023 — 403 drugs reviewed

A systematic review mapping CBD's enzymatic profile onto the broader prescription drug catalog. Stöllberger and colleagues reviewed 403 frequently prescribed CYP-substrate medications and found theoretical pathway overlap with 67–68% of them. "Theoretical" is the right word — pathway overlap is necessary but not sufficient for a clinically meaningful interaction. Many of those 270-plus drugs interact with CBD only at very high CBD doses or only in pharmacogenomically susceptible patients.

Nachnani 2024 — real-world cases

A systematic review of 31 published reports covering 889 patients on CBD with concomitant prescriptions. Nachnani 2024 documented warfarin, valproate, and tacrolimus interactions specifically; 58% of cases showed unexpected serum-level changes after CBD initiation. Real-world data, not RCT — but corroborating the mechanism Bansal quantified.

Geffrey 2015 — pediatric epilepsy and clobazam

Pediatric epilepsy patients on clobazam (a CYP3A4 + CYP2C19 substrate) had clobazam plasma levels rise by 60% and active-metabolite levels rise by 500% after starting CBD. Geffrey 2015 is older than Bansal but more dramatic in magnitude — and clinically illustrative: this is what shared-pathway accumulation looks like at high CBD doses in a vulnerable cohort.

Why the sublingual route matters

One detail meaningfully changes the CBD-drug-interaction picture: how you take the oil.

When you swallow CBD oil and it travels through the GI tract, it enters the liver via the portal vein before reaching systemic circulation. That's first-pass metabolism. The liver is full of CYP enzymes; some CBD gets metabolized on this first pass, and CBD inhibits those CYP enzymes during transit. Oral bioavailability is roughly 6% for swallowed CBD (Millar 2018), and CYP-pathway interaction is at its strongest in that swallowed-bolus form.

Sublingual administration bypasses most of that. The sublingual mucosa has dense capillary networks. CBD held under the tongue for 60–90 seconds is absorbed directly into the systemic circulation, bypassing the GI tract and the liver's first-pass system. Sublingual bioavailability is roughly 13–19% — more than double swallowed-fast oral. More importantly for the interaction picture: less CBD passes through the liver in concentrated bolus form, meaning less CYP enzyme inhibition at the moment of intake.

Practical implications:

• Customers using Reclaim's oil per instruction (sublingual hold 60–90 seconds, with a high-fat meal per Taylor 2018) likely have a meaningfully lower CYP-interaction profile than the Bansal 2023 subjects on 750mg-equivalent swallowed CBD.
• This doesn't eliminate the interaction — CBD still circulates and still inhibits CYP enzymes. But the magnitude per dose is plausibly smaller than the oral-swallow research suggests.
• The combination of (a) wellness doses, (b) sublingual administration discipline, and (c) prescriber awareness produces a much more tolerable picture than headline-research numbers imply.

What we don't know

Most CBD-Rx interaction evidence comes from healthy adults at therapeutic-CBD doses (200–800mg/day for epilepsy or research). At wellness CBD doses administered sublingually, magnitude is meaningfully smaller — but we don't have RCTs at every dose × medication × administration-route combination. Pharmacogenomic variation (the Anderson 2022 CYP2D6 case) means the same dose has different effects in different people. Liver-enzyme elevations (Devinsky 2018: ALT/AST elevated 5–20% in Lennox-Gastaut patients on concomitant valproate) are documented at high CBD doses with hepatotoxic co-medications.

We are not telling you 25mg of sublingual CBD will not affect your warfarin INR. We're telling you the mechanism is real, the in-practice magnitude at this format and dose is modest for most users, and the safe move is still to talk to your prescriber. Many of our customers, including our founder, have safely combined CBD with multiple prescriptions under prescriber supervision.

What to discuss with your prescriber

1. The medication name(s) and dose you're on.
2. The CYP pathway involved — link them the per-medication page above if helpful.
3. Whether your dose can be monitored (INR for warfarin, drug-level testing for tacrolimus, LFTs for high-load combinations, TSH for long-term CBD on levothyroxine).
4. Whether your prescriber recommends a CBD dose ceiling, a timing separation (e.g. CBD AM, Rx PM), or against combining altogether.
5. Bring a printout — this page, or the per-medication detail. Bring your COA too if the prescriber wants to verify what's in the product.

The titration protocol applies as written when combining CBD with prescription medications — the difference is that interaction-aware monitoring matters more.

Red flags that need a prescriber conversation, not just our content

By drug class and condition

DMARDs (MTX, plaquenil, biologics)

Autoimmune cohort. See related conditions: rheumatoid arthritis, lupus, psoriatic arthritis.

NSAIDs (celecoxib, meloxicam, ibuprofen)

Joint and musculoskeletal pain cohort. See related conditions: knee osteoarthritis, back pain, masters-athlete recovery.

SSRIs / benzodiazepines

Sleep and stress cohort. See related conditions: anxiety, insomnia.

Statins / blood thinners / BP medications / levothyroxine

Inflammaging cohort. See related conditions: inflammaging, women 40+.